Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

The new Prime video movie, “Deep Cover” is now playing and it follows what hijinks would ensue when improv actors go undercover as dangerous criminals. WGNO’s Kenny Lopez spoke ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Sens. Bernie Sanders (I-Vt.) and Angus King (I-Maine) have introduced legislation that would ban direct-to-consumer drug ads.

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Deep Apple Therapeutics, Inc. has announced a research collaboration and exclusive worldwide license agreement with Novo ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk ...

Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research ...